Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22002182 | 0.74 | — | — | |
| SCHEMBL9912192 | 0.69 | ALDH1A1 (0.40) | EPHX1MEN1KMT2APOLBKDM4E | |
| SCHEMBL14617948 | 0.69 | ALDH1A1 (0.38) | KMT2A | |
| SCHEMBL18612606 | 0.69 | CA12 (0.36) | MEN1KMT2APOLB | |
| SCHEMBL17614835 | 0.69 | POLB (0.41) | EPHX1MEN1KMT2APOLB | |
| SCHEMBL23964452 | 0.67 | POLB (0.37) | POLB | |
| SCHEMBL23897409 | 0.67 | LMNA (0.33) | EPHX1MEN1KMT2APOLB | |
| SCHEMBL17614232 | 0.67 | MEN1 (0.48) | EPHX1MEN1KMT2ANOS1 | |
| SCHEMBL133932 | 0.65 | NPC1 (0.44) | EPHX1MEN1KMT2APOLBKDM4E | |
| SCHEMBL6859267 | 0.65 | KDM4E (0.46) | EPHX1MEN1KMT2APOLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099972-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | UNIV DREXEL (US) | 2018-04-12 | — | — | US | disclosed |
| US-9856260-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160264587-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | UNIV DREXEL (US) | 2016-09-15 | — | — | US | disclosed |
| US-9375474-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2016-06-28 | — | — | US | disclosed |
| US-20160082123-A1 | Hydrogel-Linked Prodrugs Releasing Tagged Drugs | ASCENDIS PHARMA A/S (DK) | 2016-03-24 | — | — | US | disclosed |
| US-9068046-B2 | Sulfur-containing oligomer and dendrimer of acrylate and preparation methods thereof | ETERNAL MATERIALS CO., LTD. (TW) | 2015-06-30 | — | — | US | disclosed |
| US-20140171597-A1 | SULFUR-CONTAINING OLIGOMER AND DENDRIMER OF ACRYLATE AND PREPARATION METHODS THEREOF | ETERNAL MATERIALS CO., LTD. (TW) | 2014-06-19 | — | — | US | disclosed |
| US-20130156761-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | Alliance Discovery, Inc. (US) | 2013-06-20 | — | — | US | disclosed |
| US-8435993-B2 | Methods of inhibiting metastasis from cancer | PHILADELPHIA HEALTH AND EDUCATION CORPORATION (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120141471-A1 | Methods of Inhibiting Metastasis from Cancer | Alliance Discovery, Inc. | 2012-06-07 | — | — | US | disclosed |
| US-7173004-B2 | Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099972-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | CX3CR1, CCL2, CCR5 | EPHX1 761/4885MEN1 592/4885KMT2A 3816/4885 |
| US-20120141471-A1 | Methods of Inhibiting Metastasis from Cancer | CX3CR1, CXCR3, CCR5 | EPHX1 729/4885MEN1 735/4885KMT2A 3447/4885 |
| US-20130156761-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | CX3CR1, CCL2, CCR5 | EPHX1 761/4885MEN1 592/4885KMT2A 3816/4885 |
| US-20160082123-A1 | Hydrogel-Linked Prodrugs Releasing Tagged Drugs | PTMS, PGLS, PAM | EPHX1 164/4885MEN1 3497/4885KMT2A 2556/4885 |
| US-20160264587-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | CX3CR1, CCL2, CCR5 | EPHX1 761/4885MEN1 592/4885KMT2A 3816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.